Volume 29, Number 11—November 2023
Research
SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020–2022
Table 2
HIV status at first SARS-CoV-2 infection | Total no. (%) persons, n = 453,587 (%) | Total no. (%) events, n = 23,834 | Unadjusted rate ratio (95% CI) | p value | Adjusted rate ratio (95% CI)† | p value |
---|---|---|---|---|---|---|
PWH | 2,886 (0.6) | 192 (0.8) | 1.32 (1.15–1.51) | <0.0001 | 1.46 (1.27–1.68) | <0.0001 |
PWOH | 450,701 (99.4) | 23,642 (99.2) | Reference | Reference |
*Estimates describe exponentiated estimates from a Poisson regression model using the logarithm of person-time as the offset term. Bold text indicates statistical significance at p<0.05. PWH, persons with HIV; PWOH, persons without HIV. †Multivariable Poisson regression model controlled for the following covariates: age, sex at birth, ethnicity and race, region of residence, initial SARS-CoV-2 infection group, vaccination status at the time of first SARS-CoV-2 infection, vaccination type, and number of doses administered after the first SARS-CoV-2 infection.
Page created: September 06, 2023
Page updated: October 23, 2023
Page reviewed: October 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.